NordMedica is a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical and medical products in specific therapeutic areas. Since January 2013, NordMedica is part of the Netherlands based Eurocept Group.
NordMedica’s focus product is amsacrine, an aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias. It is frequently used in combination with other neoplastic agents in chemotherapy protocols. Amsacrine is also known by its brand names: Amsidine®, Amekrin®, Amsidyl®, Amsadina® and is marketed via the Eurocept Group’s operational company: Eurocept International BV.
If you have any enquiries, please contact: Eurocept International BV Trapgans 5 1244 RL Ankeveen Netherlands phone: +31-35-528-3957 email: nordmedica@eurocept.nl